No luck for Sanofi ($SNY) in turning over a Plavix antitrust fine. A Paris appeals court has upheld the €40.6 million ($49.7 million) penalty for trying to keep doctors and pharmacists from prescribing or subbing copycat versions of the former blockbuster blood thinner, Law360 reports. The French Competition Authority handed down the original decision in May 2013, saying the pharma giant abused its dominance and employed a "strategy of denigration" against generic rivals in 2009 and 2010. Story (sub. req.) | More